You are here:

Sertraline (Lustral®)


Following a full submission.

Not recommended for use within NHS Scotland.

Sertraline has demonstrated some benefit in treating post-traumatic stress disorder (PTSD) in two of four 12-week double blind treatment studies, and in extension studies for up to 64 weeks. The product licence restricts its use to women only; a narrower indication than for the other drug currently licensed for treating PTSD, and against which no comparative trials has been conducted. The manufacturer submitted no evidence to demonstrate the costeffectiveness of their drug.

Drug Details

Drug Name: Sertraline (Lustral®)
SMC Drug ID: 68/03
Manufacturer: Pfizer Ltd
Indication: Post-traumatic stress disorder in women
BNF Category:
Sub Category: 4.3 Antidepressant drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 10 November 2003